ICOSLG and breast cancer: Furthermore, a subset of B cells expressing inducible T-cell costimulator ligand (ICOS-L) appeared after neoadjuvant chemotherapy in breast cancer patients and aggregated in the intra-tumoral TLS; this process triggered a T-cell response as part of the antitumor response and was associated with favorable clinical outcomes in these patients (150).